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ABSTRACT
Background and Objectives: We sought to investigate an anti-atherosclerotic and anti-
inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic 
atherosclerotic rabbit model.
Methods: Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet 
for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits 
were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 
for each group). All lesions were assessed with angiography, optical coherence tomography 
(OCT), and histological assessment.
Results: Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p<0.01) and lipid accumulation 
(18.90±3.63% vs. 10.20±2.03%, p=0.047) was significantly decreased by SGLT-2 inhibitor 
treatment. The SGLT-2 inhibitor group showed lower macrophage infiltration (20.23±1.89% 
vs. 12.72±1.95%, p=0.01) as well as tumor necrosis factor (TNF)-α expression (31.17±4.40% 
vs. 19.47±2.10%, p=0.025). Relative area of inducible nitric oxide synthase+ macrophages 
was tended to be lower in the SGLT-2 inhibitor-treated group (1.00±0.16% vs. 0.71±0.10%, 
p=0.13), while relative proportion of Arg1+ macrophage was markedly increased (1.00±0.27% 
vs. 2.43±0.64%, p=0.04). As a result, progression of atherosclerosis was markedly attenuated 
in SGLT-2 inhibitor treated group (OCT area stenosis, 32.13±1.20% vs. 22.77±0.88%, p<0.01). 
Mechanistically, SGLT-2 treatment mitigated the inflammatory responses in macrophage. 
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Especially, Toll-like receptor 4/nuclear factor-kappa B signaling pathway, and their 
downstream effectors such as interleukin-6 and TNF-α were markedly suppressed by SGLT-2 
inhibitor treatment.
Conclusions: These results together suggest that SGLT-2 inhibitor exerts an anti-
atherosclerotic effect through favorable modulation of inflammatory response as well as 
macrophage characteristics in non-diabetic situation.
Keywords: Atherosclerosis; Sodium-glucose transporter-2; Sodium-glucose transporter 2 
inhibitors; Macrophages
INTRODUCTION
The leading cause of death worldwide is cardiovascular disease (CVD), and its primary cause is 
atherosclerosis.1) Complex inflammatory and immune responses contribute to the progression 
of atherosclerosis,2) with macrophages playing a pivotal role.3)4) Recently, sodium-glucose 
cotransporter-2 (SGLT-2) inhibitors have been developed as novel therapeutic agents for 
the treatment of patients with diabetes mellitus (DM). SGLT-2 is expressed primarily in the 
S1 and S2 segments of the kidney proximal tubule, where 90% of primary urinary glucose 
is resorbed.5)6) Several clinical trials have shown that dapagliflozin, one of the best-known 
SGLT-2 inhibitor drugs, can be used alone to treat DM patients, effectively lowering both 
fasting blood glucose and glycosylated hemoglobin. In addition to blood sugar normalization, 
dapagliflozin is known to improve CVD outcomes by reducing blood pressure, body weight, 
fat mass, triglyceride and uric acid levels, and improving insulin resistance.7-10) Other studies 
have reported that SGLT-2 inhibitors can reduce inflammatory responses and oxidative stress, 
thereby decreasing the progression of atherosclerosis in diabetic animal models.11-13) Together, 
these findings imply that SGLT-2 inhibitors have pleiotropic beneficial effects to ameliorate 
the progression of atherosclerosis and other CVD. However, detailed mechanisms of these 
effects have not been elucidated. Recently, it was reported that SGLT-2 inhibitors reduce 
the proportion of macrophage infiltration in atherosclerotic plaques through an unknown 
mechanism. It is an intriguing possibility that SGLT-2 inhibitors may affect macrophage 
polarization and expression of inflammatory cytokines. To address these questions, the 
present study aimed to evaluate the preventive effect of dapagliflozin on the development of 
atherosclerotic lesions in a normoglycemic rabbit model. Furthermore, we have investigated 
changes in polarization of M1 and M2 macrophages, as well as the expression of interleukin 
(IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and other inflammatory mediators as potential 
components in the mechanism by which SGLT-2 inhibitors protect against atherosclerotic 
progression in non-diabetic conditions.
METHODS
Rabbit model of atherosclerosis
The local Institutional Animal Care and Use Committee (IACUC) of Yonsei University Health 
System approved the study protocol (IACUC: 2016-0157). A total of 26 male New Zealand 
white rabbits (3.0–3.5 kg) were acclimatized for one week, housed at room temperature with 
a 12-hour light cycle and free access to standard diet and water. At the start of the experiment 
(Figure 1), all rabbits were provided with a high-cholesterol diet (1% cholesterol; Dooyeol 
Biotech, Seoul, Korea), which was maintained for 8 weeks, followed by 2 weeks of normal 
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diet. Surgery to induce the development of atherosclerotic lesions took place 1 week after 
initiating the cholesterol diet. After surgery, rabbits were randomly assigned to experimental 
and control groups (n=13 each). The experimental group was treated with SGLT-2 inhibitor 
(dapagliflozin, 1 mg/kg/day) for 8 weeks after surgery.
The surgery to initiate atherosclerosis comprised endothelial denudation of the abdominal 
aorta using a balloon catheter. Animals were pretreated with antibiotics and analgesics. 
Anesthesia was induced by intramuscular injection of an appropriate mixture of Zoletil 
(0.2 mL/kg; Virbac New Zealand, Hamilton, New Zealand) and Rompun (0.1 mL/kg; Bayer, 
Leverkusen, Germany), then maintained with 1.5% isoflurane (Forane; JW Pharmaceutical, 
Seoul, Korea) and oxygen. Heparin (200 U/kg) was injected to maintain an activated clotting 
time >250 seconds before catheterization. Access to the aorta with a 30-mm-length balloon 
catheter was obtained through the carotid artery. Based on quantitative angiography, 
balloon over-inflation was applied 2 times, for 30 seconds each, with a balloon:vessel ratio of 
1.2:1.0. Angiography and optical coherence tomography (OCT) were performed immediately 
post-procedure and again at the follow-up, 8 weeks post-procedure (Figure 1). At that time, 
animals were euthanized. After autopsy, affected arteries and other organs were collected for 
histology. A 30-mm section of aorta was dissected into 4 parts and stored for analyses.
Angiography analysis
Quantitative aorta angiography analysis was performed before modeling, and at the terminal 
procedure using the QAngio XA 7.1 Medis System (Medis Medical Imaging Systems, Leiden, The 
Netherlands). All angiograms were analyzed in an independent core laboratory (Cardiovascular 
Research Center, Seoul, Korea) using the same analysis method as in our previous study.14)
Optical coherence tomography analysis
OCT images were obtained using the LightLab Imaging C7-XR imaging system (St. Jude 
Medical, St. Paul, MN, USA), with contrast agent at a 1:1 ratio with saline. Data were acquired 
continuously and stored digitally for later analysis, as described previously.14)
Blood analysis
Blood samples were obtained from the ear vein of rabbits fasted overnight. Samples were 
collected prior to the start of the study and at the follow-up. Plasma levels of total cholesterol 
(TC), triglyceride, and low- and high-density lipoprotein cholesterol (LDL-C, HDL-C) were 
measured by DRI-CHEM 4000i (Fujifilm, Tokyo, Japan).
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Figure 1. Schematic design of the study protocol. After 1 week of a high-cholesterol diet, balloon injury was 
induced in the abdominal aorta. Rabbits then received a SGLT-2i, depending on their group assignment, for 8 
weeks. Blood was collected baseline and before sacrifice at the end. OCT was assessed at the end of the study, 
and then the aorta was harvested. 
OCT = optical coherence tomography; SGLT-2i = sodium-glucose cotransporter-2 inhibitor.
Morphological analysis
At the time of sacrifice, 5 mm of aorta tissue was fixed overnight in 10% normal buffered 
formalin before histological processing. Paraffin sections (4 μm) were cut on a microtome 
(Leica RM2235; Leica, Wetzlar, Germany), mounted on microscope slides (Fisherbrand 
Superfrost Plus; Fisher Scientific, Waltham, MA, USA), and stained with hematoxylin and 
eosin (H&E), Masson's trichrome, and Movat's pentachrome. For Oil Red O (ORO) lipid 
staining, frozen 5-mm specimens of vessel were sectioned (10 μm) on a microtome (Leica 
CM1860; Leica) and then mounted.
Immunohistochemical analysis
Macrophage and inflammation expression were evaluated by Immunohistochemical (IHC) 
analysis following a general IHC protocol. Tissue sections were immunostained at 4°C 
overnight with antibody against the macrophage marker RAM11 (DAKO, Santa Clara, CA, 
USA), or with antibodies against the inflammatory markers: TNF-α (ABCAM, Cambridge, 
United Kingdom), IL-1β (NOVUS, Littleton, CO, USA), or IL-6 (Santa Cruz Biotechnologies, 
CA, USA). The primary antibody was detected using a peroxidase-based kit (DAKO, Glostrup, 
Denmark), and visualized using 3,3′-diaminobenzidine substrate with enhancer (DAKO). 
The sections were subsequently counterstained with hematoxylin (DAKO). Digital images 
of the vessels were scanned using a SCN400 scanner (Leica), and histomorphometry was 
performed using LAS 4.2 software (Leica).
Immunofluorescence analysis using the confocal microscopy
Vessel tissue sections were micro-cut at room temperature, then deparaffinized through the 
dewatering process. Subsequently, the sections were triply immunostained at 4°C overnight 
with antibodies against CD68 (Thermo Scientific, Long Beach, NY, USA), inducible nitric 
oxide synthase (iNOS; Santa Cruz Biotechnologies) for M1 macrophages, and arginase-1 
(Arg-1; Santa Cruz Biotechnologies) for M2 macrophages. The sections were washed for 
10 minutes in 1% phosphate-buffered saline (PBS), and then incubated with fluorescein 
isothiocyanate, phycoerythrin, and Texas Red-conjugated secondary antibodies (Santa Cruz 
Biotechnologies), respectively, for 1 hour in the dark at room temperature. The sections 
were washed in PBS for 10 minutes, mounted with Fluoroshield containing 4′,6-diamidino-
2-phenylindole (ImmunoBioscience, Mukilteo, WA, USA), and stored in the dark at 4°C. 
Phosphorylated NF-κB (pNF-κB, p65, sc-8008; Santa Cruz Biotechnologies) staining was 
performed in the same method. Confocal microscopy was performed with an LSM 700 
system (Carl Zeiss, Oberkochen, Germany).
Real-time reverse transcription-polymerase chain reaction
Total RNA was isolated from a 10-mm length of aorta tissue using QIAzol reagent (QIAGEN, 
Hilden, Germany). Complementary DNA was synthesized using Quantitect Reverse 
Transcription Kit (QIAGEN), then real-time polymerase chain reaction (PCR) involving the 
use of the SYBR Green kit of 2X Fast Q-PCR Master Mix (SMOBIO, Hsinchu City, Taiwan). 
The following rabbit primer sequences were used: IL-1β, forward 5′-TTG AAG AAG AAC 
CCG TCC TCT G-3′ and reverse 5′-CTC ATA CGT GCC AGA CAA CAC C-3′; IL-6, forward 
5′-CTA CCG CTT TCC CCA CTT CAG-3′ and reverse 5′-TCC TCA GCT CCT TGA TGG TCT 
C-3′; TNF-α, forward 5′-CTG CAC TTC AGG GTG ATC G-3′ and reverse 5′-CTA CGT GGG 
CTA GAG GCT TG-3′; iNOS, forward 5′- GAC GTC CAG CGC TAC AAT ATC C-3′ and reverse 
5′-GAT CTC TGT GAC GGC CTG ATC T-3′; Arg-1, forward 5′-AAC CCA TCT CTG GGG AAA 
AC-3′ and reverse 5′-GTC AAT TGG CTT GTG ATT GC-3′; and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), forward 5′-TGA CGA CAT CAA GAA GGT GGT G-3′ and reverse 
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5′-GAA GGT GGA GGA GTG GGT GTC-3′. The following mice primer sequences were used: 
IL-6, forward 5′-ACT TCC ATC CAG TTG CCT TCT TGG-3′ and reverse 5′-TTA AGC CTC CGA 
CTT GTG AAG TGG-3′; nuclear factor-kappa B (NF-κB), forward 5′-ACC ACT GCT CAG GTC 
CAC TGT C-3′ and reverse 5′-GCT GTC ACT ATC CCG GAG TTC A-3′; Toll-like receptor 4 
(TLR4), forward 5′-GCT CCT GGC TAG GAC TCT GA-3′ and reverse 5′-TGT CAT CAG GGA 
CTT TGC TG-3′; TNF-α, forward 5′-GCG ACG TGG AAC TGG CAG AAG-3′ and reverse 
5′-GCC ACA AGC AGG AAT GAG AAG AGG-3′; and β-actin, forward 5′-CGT TGA CAT CCG 
TAA AGA CC-3′ and reverse 5′-AAC AGT CCG CCT AGA AGC AC-3′. The conditions for 
real-time PCR were as follows: denaturation at 65°C for 2 minutes, 95°C for 10 minutes, then 
the 40 cycles at 95°C for 15 seconds and 60°C for 60 seconds, dissociation curve 95°C for 15 
seconds, 60°C for 15 seconds and 95°C for 15 seconds. Relative mRNA levels were determined 
by comparison to GAPDH or β-actin mRNA: relative mRNA expression = 2[∆Ct(control)−∆Ct(target)].
Western blot analysis
Rabbit aorta (10 mm length) was lysed with radioimmunoprecipitation assay buffer 
(Biosesang, Seongnam, Korea) containing cOmplete Mini, ethylenediaminetetraacetic 
acid-free protease inhibitor cocktail (Roche, Basel, Switzerland). The protein samples 
were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then 
electrotransferred to Immuno-Blot PVDF membrane (Bio-Rad, Hercules, CA, USA). 
Membranes were blocked with 5% skim milk (Noble Bio, Hwaseong, Korea) in 10% Tris-
buffered saline containing Tween 20 (TBS-T) for 1 hour at room temperature. Membranes 
were incubated with primary antibodies against Arg-1 (BD Bioscience, San Jose, CA, USA), 
IL-6 (Santa Cruz Biotechnologies), iNOS (Santa Cruz Biotechnologies), TLR4 (Santa Cruz 
Biotechnologies), TNF-α (ABCAM), NF-κB (p65; Enzo Life Sciences, Farmingdale, NY, 
USA), and pNF-κB (p65; Santa Cruz Biotechnologies) 4°C overnight, washed with TBS-T. 
The incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour room 
temperature, and then subjected to enhanced chemiluminescence (GE Healthcare, Chicago, 
IL, USA) detection. GAPDH was detected on the same membrane to serve as a loading 
control. Densitometry analysis was performed using Image J software (National Institutes of 
Health, Bethesda, MD, USA).
Cell culture
Cells of the mouse macrophage cell line Raw 264.7 were cultured in RPMI 1640 containing 
10% fetal bovine serum (both from Biowest, Riverside, MO, USA), supplemented with 10% 
non-essential amino acids, 1% 2-mercaptoethanol, and 10% penicillin (all from Gibco, 
Carlsbad, CA, USA). Cells were maintained at 37°C in humidified air with 5% carbon dioxide. 
Inflammation analysis methods were the same as in our previous study.15) Before treatment, 
cells were washed twice with pH 7.4 PBS (Gibco). Cells were then incubated with 0.1 µg/mL 
lipopolysaccharide (LPS) for 1 hour, then with 2 mM ATP for 0.5 hour, followed by treatment 
with 30 µM dapagliflozin (Sigma-Aldrich, St. Louis, MO, USA). For NF-κB inhibition, QNZ 
(EVP4593; Selleckchem, Houston, TX, USA) was used as 0.1 µM for 1 hour pretreatment.
Cell transfection
The siRNA targeting mouse SGLT-2 (5′-UGUUCAGAACCAAUAGAGGCACAgt-3′) were 
synthesized by Bioneer (Daejeon, Korea) and the control siRNA was purchased from Santa 
Cruz Biotechnologies (Control siRNA-A). Then, the siRNAs were transfected to RAW264.7 
cells using LipofectamineTM RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer's recommendations and were incubated in cell culture medium for 4 
hours. After transfection, medium was replaced with fresh medium for 1 day, and then the 
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expression level of SGLT-2 was analyzed. Compared with control siRNA which showed a 
negligible effect on the SGLT-2 expression, SLGT-2 siRNA (30 nM) effectively suppressed the 
transcriptional and translational level of SGLT-2 (Supplementary Figure 1A and 1B).
Statistical analysis
Data are expressed as mean±standard error of the mean. Statistical analyses were performed 
using SPSS v23.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were compared using one-
way analysis of variance. The p values less than 0.05 were considered statistically significant.
RESULTS
Anti-atherosclerotic effects confirmed by angiographic and optical 
coherence tomography imaging analysis
Angiographic analysis at 8 weeks after balloon injury demonstrated significantly lower stenosis 
diameter in the SGLT-2 inhibitor-treated group than the control group (9.65±0.38% vs. 
20.59±1.94%, p<0.001, Figure 2A). Figure 2B displays representative OCT images of lipid and 
macrophage accumulation in the plaques. This, too, showed significantly lower stenosis (as area 
percent) in the inhibitor-treated group (22.56±0.80% vs. 32.13±1.20%, p<0.001, Figure 2B).
Blood lipids and histological analysis
There were no significant differences between the groups in body weight, blood glucose or 
plasma cholesterol levels at baseline, or at follow-up (Table 1). The lipid profile at follow-
up, including TC and LDL-C were unaffected by SGLT-2 inhibitor treatment compared 
with the control group (TC, 381.43±106.89 mg/dL vs. 463.71±116.93 mg/dL, p=0.61; LDL-C, 
336.76±102.75 mg/dL vs. 417.37±111.36 mg/dL, p=0.60). However, the atheromatous plaque 
ratio revealed by H&E and trichrome staining was substantially decreased in the SGLT-
2 inhibitor-treated group compared to the control group (21.91±1.22% vs. 38.51±3.16%, 
p<0.001, Figure 2C and 2D). Lipid accumulation in aorta, by ORO staining, was also 
attenuated in the inhibitor-treated group (10.20±2.03% vs. 18.90±3.63%, p=0.047, Figure 2E).
Immunohistochemical analysis to assess macrophage infiltration and 
expression of inflammatory markers
Macrophage infiltration plays a central role in the initiation and progression of atherosclerosis. 
Using IHC staining of RAM11 within plaques, we demonstrated that macrophage infiltration 
was significantly lower in the SGLT-2 inhibitor-treated group compared with the control group 
(13.69±2.17% vs. 17.00±2.50%, p=0.011, Figure 3A). The inflammatory content of plaques was 
assessed by immunostaining for TNF-α, IL-1β and IL-6, and we observed all 3 to be significantly 
decreased in the SGLT-2 inhibitor-treated group (TNF-α, 19.47±2.10% vs. 31.17±4.40%, 
p=0.025; IL-1β, 9.08±1.76% vs. 28.57±3.69%, p<0.001; IL-6, 10.17±1.02% vs. 19.88±3.11%, 
p=0.007, Figure 3B-3D). These results together indicated that SGLT-2 inhibitor can reduce 
inflammatory processes in the milieu of atherosclerotic plaques.
Macrophage polarization in atherosclerotic plaques assessed by 
immunofluorescence stain
We used immunofluorescence co-stain to assess macrophage polarization within plaques 
(Figure 4A). The relative area containing M1-subtype macrophages, represented by iNOS+ 
staining, was somewhat lower in the SGLT-2 inhibitor-treated group compared with the 
control group (0.71±0.10% vs. 1.00±0.16%, p=0.130, Figure 4B). Conversely, the presence 
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Figure 2. Imaging analyses for the progression of atherosclerosis. (A) Angiography compared diameter stenosis 
of each group at baseline and follow up. (B) OCT images showing area stenosis for each group. The red arrows 
point to the lipid. (C) Tissues were stained with H&E, ORO, trichrome and pentachrome. (D) Atheromatous plaque 
for vessels in each group. (E) Lipid accumulation of plaques analyzed by ORO staining. Scale bars represent 100 
µm. Data are mean±standard error of the mean. 
Dapa = dapagliflozin; H&E = hematoxylin and eosin; OCT = optical coherence tomography; ORO = Oil Red O. 
*p<0.05 vs. Control group.
Table 1. Plasma lipid concentrations
Variables
Baseline Follow-up
Control (n=13) Dapagliflozin (n=13) Control (n=13) Dapagliflozin (n=13)
Body weight (kg) 3.30±0.06 3.20±0.08 3.63±0.07 3.53±0.06
Blood glucose (mg/
dL)
103.50±1.73 105.64±2.97 129.00±4.00 131.71±4.05
TC (mg/dL) 28.29±2.57 26.79±3.20 463.71±116.93 381.43±106.89
TG (mg/dL) 47.07±6.44 41.43±6.26 24.21±6.84 21.93±8.70
LDL-C (mg/dL) 0.63±1.76 1.43±1.30 417.37±111.36 336.76±102.75
HDL-C (mg/dL) 19.50±1.57 19.93±2.94 41.50±5.75 40.29±4.07
Values are mean±standard error of the mean.
TC = total cholesterol; TG = triglyceride; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density 
lipoprotein cholesterol.
of M2 macrophages, revealed by Arg-1 staining, was significantly increased in the SGLT-2 
inhibitor-treated group (2.43±0.64% vs. 1.00±0.27%, p=0.044, Figure 4C). Consequently, 
the Arg1/iNOS ratio was significantly greater in the SGLT-2 inhibitor-treated group compared 
with the control group (2.46±0.36% vs. 1.00±0.18%, p=0.001, Figure 4D), demonstrating 
a strong effect of SGLT-2 inhibitor on macrophage polarization. We further investigated 
whether SGLT-2 inhibitor treatment affects the activation of NF-κB, which is a well-
recognized major regulator of inflammatory response in the vascular endothelial cells and 
macrophages by immunofluorescence staining for the pNF-κB. Nuclear localization of 
pNF-κB was shown to be mitigated in the aorta wall vascular cells of the rabbit administered 
with SGLT-2 inhibitor (Supplementary Figure 2A). Furthermore, in vitro experiment also 
demonstrated that SGLT-2 inhibitor treatment mitigated the nuclear localization of pNF-κB 
similar to that of NF-κB inhibitor (QNZ) treatment (Supplementary Figure 2B).
Expression of inflammatory marker mRNA and protein in atherosclerotic 
plaques
IHC evidence for the effects of SGLT-2 inhibitor on inflammatory markers in atherosclerotic 
plaques was confirmed using molecular and immunobiochemical analyses. Relative mRNA 
expression levels of TNF-α, IL-1β, IL-6, iNOS, and Arg-1 in each group are presented in Figure 5.  
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Figure 3. IHC staining of macrophage and inflammation markers. (A) Tissues immunologically stained of RAM11 
positive area. (B) Tissues immunologically stained of TNF-α positive area. (C) Tissues immunologically stained of 
IL-1β positive area. (D) Tissues immunologically stained of IL-6 positive area. Scale bars represent 100 µm. Data 
are mean±standard error of the mean. 
Dapa = dapagliflozin; IHC = immunohistochemical; IL = interleukin; TNF = tumor necrosis factor. 
*p<0.05 vs. Control group.
The expression of IL-1β mRNA were significantly decreased in the SGLT-2 inhibitor-treated 
group compared with the control group (IL-1β, 2.77±0.42 vs. 3.83±0.94, p=0.05, Figure 5A). IL-6, 
TNF-α and iNOS mRNA were somewhat lower in the SGLT-2 inhibitor-treated group compared 
with the control group (IL-6, 0.64±0.17 vs. 2.26±1.10, p=0.09; TNF-α, 0.61±0.12 vs. 0.95±0.19, 
p=0.59; iNOS, 0.35±0.12 vs. 1.02±0.63, p=0.1, Figure 5B-5D). Conversely, mRNA expression of 
Arg-1, as well as the ratio of Arg-1/iNOS, were somewhat higher in the SGLT-2 inhibitor-treated 
group compared with the control group (Arg-1, 0.31±0.03 vs. 0.25±0.07, p=0.16; Arg-1/iNOS 
ratio, 3.43±0.93 vs. 1.75±0.44, p=0.02, Figure 5E and 5F). The results for protein expression 
of TNF-α, NF-κB, iNOS, and Arg-1 were similar to the results for relative mRNA expression 
(TNF-α, 0.65±0.12 fold vs. 1.00±0.14, p=0.068; NF-κB, 0.56±0.14 vs. 1.00±0.16, p=0.016; iNOS, 
0.68±0.14 vs. 1.00±0.17, p=0.148; Arg-1, 1.47±0.28 vs. 1.00±0.16, p=0.156, Figure 5G-5J). As a 
result, the ratio of Arg-1/iNOS protein was significantly greater in the SGLT-2 inhibitor-treated 
group compared with the control group (2.22±0.20 vs. 1.00±0.09, p<0.001, Figure 5K).
Treatment of RAW 264.7 macrophages with dapagliflozin reduces in vitro 
inflammatory marker expression
To confirm apparent anti-inflammatory effects of SGLT-2 inhibitor, we evaluated 
the expression profile of inflammatory markers in RAW264.7 macrophage cells after 
pretreatment with the inhibitor. Relative mRNA and protein levels in response to LPS are 
presented in Figure 6. LPS-induced expression of inflammatory mediators including TLR4, 
NF-κB, IL-6 and TNF-α were significantly attenuated by pre-treatment of SGLT-2 inhibitor 
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Figure 4. Macrophage polarization assessed by confocal immunofluorescence microscopy. (A) Confocal 
immunofluorescence microscopy showing CD68 (green), iNOS (red), and Arg-1 (white) localization in the same 
vessel. Blue represents 4′,6-diamidino-2-phenylindole staining of nuclei. (B) Relative area of CD68–iNOS staining 
in each group. (C) Relative area of CD68–Arg-1 staining in each group. (D) Arg-1/iNOS ratio in each group. n=10 
(each slide of 3 sections). Relative area measurements were determined using a Zeiss LSM 700. Scale bars 
represent 100 µm. Data are mean±standard error of the mean. 
Arg-1 = arginase-1; Dapa = dapagliflozin; DAPI = 4′,6-diamidino-2-phenylindole; iNOS = inducible nitric oxide synthase. 
*p<0.05 vs. Control group.
(Figure 6A-D). Combinational treatment of cells with the NF-κB inhibitor QNZ plus SGLT-2 
inhibitor resulted in significantly decreased expression of TLR4 and IL-6 protein compared 
with the LPS group (Figure 6F and 6H). The ratio of pNF-κB relative to total NF-κB (Figure 6G) 
and TNF-α protein expression (Figure 6I) were tended to be lower in SGLT-2 inhibitor-treated 
cells compared to LPS alone. To further investigate whether SGLT-2 inhibition directly affects 
the expression of major regulators of inflammatory responses, we conducted a knockdown 
experiment using siRNA for SGLT-2 transcripts (Supplementary Figure 1A and 1B). Compared 
with control siRNA which showed a negligible effect, SGLT-2 siRNA significantly decreased 
the transcriptional level of TLR (control siRNA versus SGLT-2 siRNA; 1.39±0.14 vs. 0.97±0.13, 
Supplementary Figure 1C and D) and NF-κB control siRNA versus SGLT-2 siRNA; 2.32±0.66 vs. 
1.73±0.54, Supplementary Figure 1E).
DISCUSSION
To our knowledge, this study is the first to demonstrate that treatment with SGLT-2 inhibitor 
reduces development of atherosclerotic lesions in the normoglycemic rabbit model. Lipid 
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Figure 5. Real-time RT-PCR and Western blot analysis of aorta artery. (A-E) RT-PCR expression of IL-1β, IL-6, TNF-α, iNOS and Arg-1. Comparisons of relative 
mRNA expression, normalized to expression of GAPDH as the housekeeping gene. (F) mRNA expression of Arg-1/iNOS ratio. (G-J) Western blot expression of 
TNF-α, NF-κB, iNOS, and Arg-1. (K) Protein expression of Arg-1/iNOS ratio. Representative data showing mRNA and protein expression, normalized to expression 
of GAPDH as the housekeeping gene. Data in the bar graphs are quantified ratios of each signal relative to the signal for GAPDH, presented as fold increases. 
Data are mean±standard error of the mean. 
Arg-1 = arginase-1; Dapa = dapagliflozin; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; IL = interleukin; iNOS = inducible nitric oxide synthase; NF-κB = 
nuclear factor-kappa B; RT-PCR = reverse transcription-polymerase chain reaction; TNF = tumor necrosis factor. 
*p<0.05 vs. Control group.
accumulation, intimal proliferation, and pro-inflammatory marker levels were all suppressed 
by SGLT-2 inhibitor treatment, suggesting the drug exerts multiple beneficial anti-
atherosclerotic effects.
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Figure 6. RT-PCR and Western blot analysis of RAW264.7. (A-D) RT-PCR expression of TLR4, NF-κB, IL-6 and TNF-α. Comparisons of relative mRNA expression, 
normalized to expression of β-actin as the housekeeping gene. (E) Western blot expression of TLR4, NF-κB, IL-6 and TNF-α. (F-I) Comparisons of relative protein 
expression, normalized to expression of GAPDH as the housekeeping gene. Data in the bar graphs are quantified ratios of the each signal relative to the signal for 
housekeeping gene, presented as fold increases. Data are mean±standard error of the mean (n=6 per group). 
Dapa = dapagliflozin; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; IL = interleukin; LPS = lipopolysaccharide; NF-κB = nuclear factor-kappa B; RT-PCR = 
reverse transcription-polymerase chain reaction; TLR4 = Toll-like receptor 4;TNF = tumor necrosis factor. 
*p<0.05 vs. LPS group.
Previous clinical studies have indicated that some anti-diabetic and lipid-lowering drugs, 
such as statins and fibrates, reduce the risk of cardiovascular events in diabetic patients.16) 
Recently, dapagliflozin has been recognized as a potent anti-diabetic drug, which inhibits 
renal glucose reabsorption by blocking SGLT-2 in the renal proximal tubule.17) Clinical 
and preclinical studies have reported beneficial effects of SGLT-2 inhibitors in preventing 
cardiovascular and atherosclerosis disease.12)18) The detailed mechanism by which SGLT-2 
exerts anti-atherosclerotic effects, and whether this is a consequence of normalizing the 
blood sugar level, had not been elucidated. By conducting both angiography and OCT 
examinations in the present study, we found that SGLT-2 inhibitor treatment markedly 
mitigated the progression of atherosclerotic plaque in the normoglycemic rabbit model 
in vivo. We confirmed that lipid accumulation and foam cell formation in the aorta were 
significantly reduced by the treatment of SGLT-inhibitor in this animal model. However, 
interestingly, SGLT-2 inhibitor treatment did not affect blood lipid profiles, implying that 
SGLT-2 inhibitors might have a direct therapeutic effect to prevent atherosclerosis.
Atherosclerosis is recognized as a chronic inflammatory disease, at all stages of which 
macrophages play a central role.3)14) M1 macrophages promote atherosclerotic plaque 
development, by promoting monocyte recruitment into plaques, and by foam cell 
formation.19) In contrast, M2 macrophages reduce atherosclerotic plaque size, cholesterol 
content, and macrophage infiltration, as well as decreasing inflammatory marker 
expression.20-22) To gain further insight into anti-atherosclerotic effects of SLGT-2 inhibitor 
in the normoglycemic rabbit model, we conducted comprehensive immunohistological 
analyses. These analyses revealed that SGLT-2 inhibitor treatment markedly reduced 
macrophage infiltration, as well as the expression of inflammatory M1 markers, including 
TNF-α, IL-1β and IL-6, which have pivotal roles in the progression of atherosclerosis.23)24) Our 
analysis also showed that SGLT-2 inhibitor treatment markedly augmented the expression of 
Arg-1, an important M2 macrophage marker. Our results are consistent with SGLT-2 inhibitor 
treatment promoting a more favorable inflammatory milieu, which suggests a potential 
mechanism for the known anti-atherosclerotic effects of SGLT-2 inhibitors.
In support of such a mechanism, we showed that dapagliflozin reduced Raw264.7 
macrophage cell expression of TLR4 and NF-κB, both well-established upstream 
regulators of inflammatory responses, resulting in reduced expression of IL-6 and TNF-α. 
To clarify whether immunomodulatory effect of dapagliflozin mainly depends on the 
blocking activity against the SGLT-2 rather than non-canonical receptor, we conducted a 
knockdown experiment targeting SGLT-2 of murine macrophage cell lines (RAW264.7) 
which modestly expresses SGLT-2. Intriguingly, SGLT-2 siRNA treatment markedly 
suppressed the transcriptional activity of TLR4, implying the direct association between 
SGLT-2 and inflammatory response. In accordance with our findings, previous in vitro 
studies have demonstrated that SGLT-2 is expressed in macrophages,25) and that treatment 
of macrophages with SGLT-2 inhibitor markedly suppresses expression of inflammatory 
cytokines.26)27) Furthermore, Mancini and colleagues have reported that canagliflozin, 
a potent SGLT-2 inhibitor similar to dapagliflozin, has been reported to suppress the 
expression of inflammatory cytokines in the vascular endothelial cells by regulating IκB 
kinase (IKK)/IκB/NF-κB signaling pathway through adenosine monophosphate-activated 
protein kinase-dependent protein kinase.26) Given that NF-κB is known to up-regulate the 
expression of inflammatory mediators including TLR4 in the nucleus upon activation by 
the inflammatory stimuli,27) it is presumable that SGLT-2 inhibitor possesses an indirect 
immunomodulatory effect via IKK/IκB/NF-κB signaling pathway, as well as direct association 
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with TLR4 signaling pathway, which should be further clarified by following studies. Those 
findings, taken together with ours, support our hypothesis that SGLT-2 inhibitors exert a 
second protective effect against atherosclerosis, which is distinct from their blood sugar 
lowering effect, and which involves direct regulation of monocyte/macrophages. To extend 
this concept of SGLT-2 inhibitor action to human atherosclerosis, further in vivo studies of 
patient samples will be required.
There were several limitations to our study. First, further studies are needed to confirm the 
proposed mechanism by which the drug suppresses atherosclerosis. Second, additional 
mechanistic studies are required to determine whether SGLT-2 is directly or indirectly 
involved. Despite these limitations, our study has been valuable in demonstrating that SGLT-
2 inhibitor treatment suppressed atherosclerosis in the normoglycemic rabbit model, and 
in its implication that SGLT-2 inhibitors convey important therapeutic benefits beyond the 
normalization of blood sugar. We suggest that SGLT-2 inhibitors may potentially be useful in 
improving CVD outcomes even for patients without diabetes.
SUPPLEMENTARY MATERIALS
Supplementary Figure 1
The effect of SGLT-2 knockdown on TLR4 and NF-κB expression. RAW264.7 cells were 
transfected with specific SGLT-2 siRNA or control siRNA. The SGLT-2 (A) protein level and 
(B) mRNA level were measured. (C) Western blot expression of TLR4, NF-κB and pNF-κB. 
(D-E) Comparisons of relative protein expression, normalized to expression of GAPDH as the 
housekeeping gene. GAPDH and β-actin were used as control. Data are mean±standard error 
of the mean (n=3 per group).
Click here to view
Supplementary Figure 2
Nuclear localization of NF-κB upon LPS-induced activation. Nuclear localization of 
NF-κB, which was activated and phosphorylated by LPS stimulation, was observed by 
immunofluorescence staining method in vivo and in vitro conditions. (A) Immunofluorescence 
staining results for pNF-KB expression in the nucleus of vascular cells of the rabbit aorta that 
was harvested at 8-weeks post balloon injury. (B) Immunofluorescence staining results for pNF-
κB expression in the nucleus of RAW264.cells stimulated by LPS.
Click here to view
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